Sol-Gel Technologies (SLGL) Stock Forecast & Price Target

Sol-Gel Technologies is expected to have strong peak annual sales thanks to their product candidate pipeline, with projected revenues of $640M by the mid-2030s due to an anticipated increase in annual pricing per patient to $250K from the prior $150K. With the potential for the drug to reach a maximum of over 2,100 patients on therapy, and the opportunity for self-commercialization in a small market of ~11K patients in the U.S., there is potential for further growth. Additionally, the company's Phase 3 program in high-frequency BCC could more than double their addressable market and lead to further gains in their stock price.

Sol-Gel Technologies is facing significant challenges with their drug candidate pipeline, most notably with the negative results from their topical erlotinib clinical study and the discontinuation of their SGT-210 program for the treatment of rare skin conditions. They have a highly risky and uncertain future, with their main value driver, SGT-610, not expected to generate revenue until late 2027 and facing a small market size of approximately 11,000 patients in the US. Combined with the company's current financials and lack of success in clinical trials, we have a negative outlook on Sol-Gel Technologies' stock.